BIOCEPT

Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid (CSF) in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). Using our proprietary CNSide™ assay to analyze and interrogate CSF-TCs and cfDNA for certain biomarkers, physicians can be better informed about the actionable molecular information associated with a patient's metastatic cancer and develop a personalized cancer treatment plan... Biocept is dedicated to supporting its partners, collaborators, and clients with our unique CNSide™ CSF-TC and cfDNA technology platforms for rare event detection and genetic characterization. Our CLIA-licensed and CAP-accredited laboratory combines a highly trained professional staff who are experienced in..

Also known as: Biocept, Inc.

Primary location: San Diego United States